Impact of NF-κB gene polymorphism on allograft outcome in Hispanic renal transplant recipients

Transplant Immunology

Volumn 28, Issue 1, 2013, Pages 18-23

  Vu, Don ^a,b,c   Tellez Corrales, Eglis ^d   Sakharkar, Prashant ^c   Kissen, Michael Scott ^e   Shah, Tariq ^b,c,f,g   Hutchinson, Ian ^a,f   Min, David I ^b,c  

^a National Institute of Transplantation Los Angeles   (United States)

^b ST VINCENT MEDICAL CENTER   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d NOVA SOUTHEASTERN UNIVERSITY   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Transplant Research Institute   (United States)

Author keywords

AR; Gene polymorphisms; Hispanics; NF B; NF B1; NF B2; NIK; Rejection; SNP; Survival; Transplantation

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEAR FACTOR KAPPA B INDUCING KINASE; NUCLEAR FACTOR KAPPA B1; NUCLEAR FACTOR KAPPA B2; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GRAFT FAILURE; GRAFT SURVIVAL; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; UNITED STATES;

ADULT; FEMALE; GENOTYPE; GRAFT REJECTION; HISPANIC AMERICANS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NF-KAPPA B; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; UNITED STATES; YOUNG ADULT;

EID: 84873055858     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.11.001     Document Type: Article

References (43)

1. Wolfe R.A., Ashby V.B., Milfrod E.L., Ojo A.O., Ettenger R.E., Agodoa L.Y., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
2. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
3. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
4. Huxford T., Ghosh G. A structural guide to proteins of the NF-kappaB signaling module. Cold Spring Harb Perspect Biol 2009, 1:a000075.
5. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109:S81-S96. [Suppl.].
6. Delhase M., Li N., Karin M. Kinase regulation in inflammatory response. Nature 2000, 406(6794):367-368.
7. Xiao G., Harhaj E.W., Sun S.C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001, 7:401-409.
8. Legarda-Addison D., Ting A.T. Negative regulation of TCR signaling by NF-kappaB2/p100. J Immunol 2007, 178:767-778.
9. Hoffmann A., Levchenko A., Scott M.L., Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002, 298:1241-1245.
10. Karin M., Lin A. NF-kappa B at the cross roads of life and death. Nat Immunol 2002, 3:221-227.
11. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
12. Chang M., Lee A.J., Fitzpatrick L., Zhang M., Sun S.C. NF-kappa B1 p105 regulates T cell homeostasis and prevents chronic inflammation. J Immunol 2009, 182:3131-3138.
13. Sriskantharajah S., Belich M.P., Papoutsopoulou S., Janzen J., Tybulewic V., Tybulewic V., et al. Proteolysis of NF-kappaB1 p105 is essential for T cell antigen receptor-induced proliferation. Nat Immunol 2009, 10:38-47.
14. Kroesen A., Loddenkemper C., Zeitz M., Visekruna A.., Joeris T., Seidel D., et al. Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006, 116:3195-3203.
15. Bellamy W., Gabrea A., Zhan F., Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
16. Schop R., Baber A., Chng W.J., Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
17. Mitsiades C.S., Mitsiades N., Hideshima T., Richardson P.G., Anderson K.C. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 2006, 7:1341-1347.
18. Csizmadia V., Gao W., Hancock S.A., Rottman J.B., Wu Z., Turka L.A., et al. Differential NF-kB and IkB gene expression during development of cardiac allograft rejection versus CD154 monoclonal antibody-induced tolerance. Transplantation 2001, 71:835-840.
19. Moreno JA, Santamaria B., Ruiz-Ortega M., Sanz A.B., Sanchez-Niño M.D., Ramos A.M., et al. NF-κB in renal inflammation. J Am Soc Nephrol 2010, 21(8):1254-1262.
20. Li Q., Verma I.M. NF-kappa B regulation in the immune system. Nat Rev Immunol 2002, 2:295-934.
21. Blanco J., Hernandez-Vargas P., Yo Y., Lopez F.O., Suzuki Y., Sanjuan G., et al. Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune gloreulonephritis. Am J Pathol 2002, 161:1497-1505.
22. Borm M.E., van Bodegraven A.A., Mulder C.J., Kraal G., Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005, 32:401-405.
23. Mirza M.M., Fisher S.A., Onnie C., Lewis C.M., Mathew C.G., Sanderson J., et al. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut 2005, 54:1205-1206.
24. Gallegos T., Potter J.J., Bailey-Wilson J.E., Karban A.S., Okazaki T., Panhuysen C.I., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004, 13:35-45.
25. Oliver J., Gomez-Garcia M., Paco L., Lopez-Nevot M.A., Pinero A., Correro F., et al. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis 2005, 11:576-579.
26. Orozco G., Sanchez E., Collado M.D., Lopez-Nevot M.A., Paco L., Garcia A., et al. Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2005, 65:183-186.
27. Greenwood C., Hamilton S., Gladman D., Butt C., Peddle L., et al. Association of nuclear factor-kappaB in psoriatic arthritis. J Rheumatol 2005, 32:1742-1744.
28. Vilchez J.R., Lopez-Nevot M.A., Garcia-Porrua C., Martin J., Perez-Armengol C., Miranda-Filloy J.A., et al. Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsyproven giant cell arteritis in northwest Spain. J Rheumatol 2006, 33:285-288.
29. Rueda B., Lopez-Nevot M.A., Ruiz M.P., Ortega E., Maldonado J., Lopez M., et al. CA microsatellite polymorphism of the nuclear factor kappa B1 gene in celiac disease. Eur J Immunogenet 2004, 3:129-132.
30. Kosoy R., Concannon P. Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type 1 diabetes. Genes Immun 2005, 6:231-235.
31. Lin S.C., Liu C.J., Yeh W.I., Lui M.T., Chang K.W., Chang C.S. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2006, 243:47-54.
32. He L.J., Lindblom A., Arbman G., Lewander A., Butchi A.K., Gao J., et al. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 2007, 42:1332-1338.
33. Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006, 210:171-186.
34. Perkins D.L., Fin P.W., Stone J.R., Boothby M.R. Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection. J Immunol 2001, 167:5994-6001.
35. Van Antwerp D., Miyamoto JS., Verma I.M., Stevenson J.K., Schwarz E.M. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995, 9:2723-2735.
36. Lee J.I., Ganster R.W., Geller D.A., Burckart G.J., Thomson A.W., Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro generated dendritic cells: association with reduced nuclear translocation of nuclear factor-kappaB. Transplantation 1999, 68:1255-1263.
37. Perry D.K., Burns J.M., Pollinger S.H., Amiot B.P., Gloor J.M., Gores G.J., et al. Proteasome inhibition causes apotosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
38. Neubert K., Meister S., Moster K., Weisel F., Maseda D., Amann K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
39. Raghavan R., Jeroudi A., Achkar K., Gaber A.O., Patel S.J., Abdellatf A. Bortezomib in kidney transplantation. J Transplant 2010, vol. 2010, Article ID 69859:6 pages.
40. Harada K.M., Mandia-Sampaio E.L., De Sandes-Freotas T.V., Felipe C.R., Park Si. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc 2009, 41:3667-3670.
41. Zheng L., Sinniah R., Hong Hsu S.I. Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem 2008, 56(5):517-529.
42. Milgrom M., Gharagozloo H., Gomez C., Contreras N., Lopez E., Esquenazi V., et al. Results of renal transplantation in Miami analyzed by race. Transplant Proc 1989, 21(6):3934-3936.
43. Higgins R.S.D., Fishman J.A. Disparities in solid organ transplantation for ethnic minorities: facts and solutions. Am J Transplant 2006, 6(11):2556-2562.